首页> 外国专利> AEROSOL COMPRISING PARTICULATE SALMETEROL, SALBUTAMOL, FLUTICASONE PROPIONATE AND/OR BECLOMETHASONE DIPROPIONATE IN A FLUOROCARBON AND/OR CHLOROFLUOROHYDROCARBON; SURFACE-TREATMENT OF THE PARTICLES WITH A LIQUID

AEROSOL COMPRISING PARTICULATE SALMETEROL, SALBUTAMOL, FLUTICASONE PROPIONATE AND/OR BECLOMETHASONE DIPROPIONATE IN A FLUOROCARBON AND/OR CHLOROFLUOROHYDROCARBON; SURFACE-TREATMENT OF THE PARTICLES WITH A LIQUID

机译:包含氟碳和/或氯氟代烃中的颗粒状沙美特罗,沙丁胺醇,丙酸氟替卡松和/或倍他米松二丙酸酯的气雾剂;液体对颗粒的表面处理

摘要

Formulation comprises a particulate medicament (I) e.g. salmeterol, salbutamol, fluticasone propionate, becolomethasone dipropionate and a fluorocarbon or hydrogen-contg chlorofluorocarbon propellant. Also claimed are the prepn of the surface-modified medicament and a canister for delivering metered doses of the aerosol formulation. Pref., (I) is salmeterol xinafoate (Ia); salbutamol sulphate; fluticascone propionate; beclomethasone dipropionate; or a combination of salmeterol xinafoate and fluticasone propionate; or salbutamol and beclomethasone dipropionate. The propellant is pref. 1,1,1,2-tetrafluoroethane (II). (I) is present in an amt. of 0.005-10% wt. based on the total wt. of the formulation e.g. a salbutamol salt and 1,1,1,2-tetrafluoroethane in a ratio of 0.05:18 by wt. Surface-modified (I) are prepd. by admixture of particulate (I) with a non-polar, non-solvent liq. followed by removal of the lid.
机译:制剂包含颗粒药物(I),例如沙美特罗,沙丁胺醇,丙酸氟替卡松,倍丙美沙美松和碳氟化合物或含氢的氯氟烃推进剂。还要求保护的是表面改性药物的制备方法和用于递送计量剂量的气雾剂制剂的罐。优选,(I)是沙美特罗西那福酯(Ia);硫酸沙丁胺醇;丙酸氟替卡松;倍氯米松双丙酸酯或沙美特罗新萘甲酸和丙酸氟替卡松的组合;或沙丁胺醇和倍氯米松双丙酸酯。推进剂是优选的。 1,1,1,2-四氟乙烷(II)。 (I)存在于amt中。 0.005-10%wt。基于总重量配方的沙丁胺醇盐和1,1,1,2-四氟乙烷的重量比为0.05:18。准备表面改性的(I)。通过将颗粒(I)与非极性,非溶剂液体混合。然后取下盖子。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号